
ESOCAP HOSTS INVESTIGATORS' MEETING FOR CONDUCT OF PHASE II ACESO STUDY



Basel, Switzerland, March 18, 2021

EsoCap AG hosted a well-attended virtual Investigators' Meeting for the ACESO study on March 18, 2021. ACESO is a randomized, placebo-controlled, double-blind trial evaluating the efficacy, tolerability and safety of ESO-101 in adult patients with active EoE (eosinophilic esophagitis).

The meeting brought together physicians, study nurses and study coordinators from 14 clinics in four countries with the teams from EsoCap and the FGK CRO (Contract Research Organization).

"This Investigators' Meeting is critical to the ACESO study's success and we are very pleased with the high attendance and great interest in the ACESO study", said Isabelle Racamier, EsoCap CEO.

Dr Alfredo Lucendo, coordinating investigator, from the Hospital General de Tomelloso in Spain added, "I look forward to working with my colleagues and their specialized clinics for patients with eosinophilic esophagitis. The ACESO trial is a unique opportunity to demonstrate the EsoCap system's effectiveness in enhancing esophageal release and deposition of ESO-101, leading to improved clinical results in EoE."

The ACESO study will include 42 patients with active EoE in 14 centers in Switzerland, Germany, the Netherlands and Spain.

About EsoCap

EsoCap AG is a privately funded company based in Basel, Switzerland.

EsoCap's vision is to improve the lives of patients with serious diseases of the upper gastrointestinal tract through development of a unique topical drug delivery platform.

Topical treatment in the upper gastrointestinal tract is extremely difficult to achieve due to ultra-short transit times with less than two seconds from the mouth to the stomach.

EsoCap owns a unique drug delivery platform allowing topical application of drug substances for local treatment of diseases of the upper gastrointestinal tract.

For more information, please visit www.esocapbiotech.com.

Contact:

Isabelle Racamier, CEO

EsoCap AG
Malzgasse 9
4052 Basel
Switzerland

isabelle.racamier@esocapbiotech.com